|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,395.00 TWD | +2.57% |
|
+20.26% | +196.81% |
| 06-18 | PharmaEssentia Rebuffs Media Report Speculating Profit, Revenue for 2026 | MT |
| 06-11 | PharmaEssentia Completes Enrollment for Phase III Primary Myelofibrosis Drug Study | MT |
Company Valuation: PharmaEssentia Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 78,065 | 143,840 | 114,578 | 204,725 | 173,829 | 505,414 | - | - |
| Change | - | 84.26% | -20.34% | 78.68% | -15.09% | 190.75% | - | - |
| Enterprise Value (EV) 1 | 75,148 | 133,629 | 94,995 | 183,725 | 153,423 | 480,249 | 476,940 | 505,414 |
| Change | - | 77.82% | -28.91% | 93.4% | -16.49% | 213.02% | -0.69% | 5.97% |
| P/E | -27.1x | -98.6x | -179x | 69.3x | 34.6x | 48x | 35.4x | - |
| PBR | 19.1x | 11.2x | 4.79x | 7.45x | 5.46x | 12.8x | 9.9x | - |
| PEG | - | 1.8x | 3x | -0x | 0.5x | 0x | 1x | - |
| Capitalization / Revenue | 119x | 49.9x | 22.4x | 21x | 11.1x | 20.5x | 13.6x | 14.2x |
| EV / Revenue | 114x | 46.4x | 18.6x | 18.9x | 9.81x | 19.4x | 12.9x | 14.2x |
| EV / EBITDA | -29x | -74.2x | -57.8x | 87.3x | 28.8x | 60.6x | 32.9x | 30.5x |
| EV / EBIT | -26.6x | -65.9x | -49.6x | 106x | 31.1x | 48.7x | 31.2x | 31.1x |
| EV / FCF | -29.7x | -73.5x | -49.8x | 102x | 41.7x | 99.2x | 115x | - |
| FCF Yield | -3.37% | -1.36% | -2.01% | 0.98% | 2.4% | 1.01% | 0.87% | - |
| Dividend per Share 2 | - | - | - | 0.9912 | 1.5 | - | 1.462 | - |
| Rate of return | - | - | - | 0.18% | 0.32% | - | 0.11% | - |
| EPS 2 | -9.732 | -4.361 | -1.739 | 8.002 | 13.59 | 28.34 | 38.41 | - |
| Distribution rate | - | - | - | 12.4% | 11% | - | 3.81% | - |
| Net sales 1 | 656.5 | 2,882 | 5,106 | 9,735 | 15,635 | 24,698 | 37,085 | 35,594 |
| EBITDA 1 | -2,595 | -1,800 | -1,645 | 2,104 | 5,327 | 7,922 | 14,475 | 16,591 |
| EBIT 1 | -2,822 | -2,028 | -1,913 | 1,736 | 4,928 | 9,867 | 15,284 | 16,243 |
| Net income 1 | -2,811 | -1,375 | -623.8 | 2,966 | 5,045 | 10,636 | 14,407 | - |
| Net Debt 1 | -2,917 | -10,211 | -19,582 | -21,000 | -20,406 | -25,165 | -28,474 | - |
| Reference price 2 | 264.03 | 429.83 | 311.79 | 554.19 | 470.00 | 1,360.00 | 1,360.00 | 1,360.00 |
| Nbr of stocks (in thousands) | 295,670 | 334,641 | 367,486 | 369,414 | 369,848 | 371,628 | - | - |
| Announcement Date | 3/2/22 | 3/1/23 | 2/27/24 | 2/26/25 | 3/3/26 | - | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 47.98x | 19.44x | 60.62x | -.--% | 15.86B | |
| 34.42x | 8.62x | 26.79x | 0.05% | 56.21B | |
| 20.89x | 6.41x | 13.9x | 1.44% | 55.38B | |
| -18.72x | 4.62x | -8.06x | -.--% | 23.75B | |
| -40.52x | 13.41x | -39.1x | -.--% | 23.19B | |
| 22.61x | 4.44x | 11.53x | -.--% | 18.14B | |
| 23.61x | 4.69x | 15.54x | -.--% | 16.84B | |
| 16.99x | 4.92x | 11.55x | -.--% | 13.56B | |
| -455.4x | 31.15x | -3472.99x | -.--% | 12.97B | |
| -73.78x | 7.58x | -67.94x | -.--% | 11.86B | |
| Average | -42.19x | 10.53x | -344.81x | 0.15% | 24.78B | |
| Weighted average by Cap. | -13.21x | 9.24x | -173.86x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 6446 Stock
- Valuation PharmaEssentia Corporation
Select your edition
All financial news and data tailored to specific country editions
